Introduction
============

As of 2010, nearly 15% of American adults had high total cholesterol, placing them at increased risk of detrimental health outcomes.[@b1-vhrm-10-615] Moreover, substantial costs are associated with high cholesterol levels, contributing to the more than US \$400 billion in direct and indirect costs associated with cardiovascular disease.[@b2-vhrm-10-615] While recent trends in uncontrolled low-density lipoprotein (LDL) may suggest that progress has been made, significant opportunity for improvement remains in the controlling of cholesterol levels.[@b3-vhrm-10-615]

While a myriad of medication options exist to treat hypercholesterolemia, and given that generic cholesterol medication availability has grown in recent years, significant barriers still limit the effectiveness of existing treatments. Specifically, medication nonadherence -- the extent to which patients take medications as prescribed -- remains prevalent and acts as a major barrier to improving health outcomes in patients with high cholesterol.[@b4-vhrm-10-615] Current estimates suggest that nonadherence to medications indicated for hypercholesterolemia results in US \$44 billion in avoidable health care costs and contributes to increased hospitalizations.[@b5-vhrm-10-615],[@b6-vhrm-10-615] While multiple investigations have aimed to curb the issue of nonadherence, more must be done to improve the medication-taking habits of patients with high cholesterol in order to decrease the risk of detrimental outcomes and reduce unnecessary health care costs.

This review highlights the current state of hypercholesterolemia treatment in the United States with a specific focus on the impact that medication nonadherence has on outcomes in patients with this condition. Furthermore, this paper examines the strategies that have been applied to date aimed at improving the use of cholesterol-lowering medications, as well as the challenges that have impeded progress. Strategies to improve adherence, from the perspective of multiple stakeholders, are also suggested to guide future interventions and patient encounters.

Scope of the problem
====================

Epidemiology
------------

Recent estimates highlight the extent of elevated cholesterol levels in the US. As of 2008, mean total serum cholesterol levels in the US for men and women were 195 mg/dL and 201 mg/dL, respectively.[@b7-vhrm-10-615] High levels of total cholesterol are noticeably higher in particular subgroups of the population, specifically non-Hispanic females and Mexican-American males; the prevalence of total cholesterol in excess of 240 mg/dL exceeds 15% in both groups.[@b8-vhrm-10-615] Additionally, approximately one in three American adults has high circulating levels of LDL cholesterol, only one-third of which has this condition under control.[@b9-vhrm-10-615] Recent data from the nationwide Reasons for Geographic and Racial Differences in Stroke study[@b10-vhrm-10-615] indicated that statins were only used by 58.4% of those with coronary heart disease (CHD), 41.7% of those with a history of stroke or abdominal aortic aneurysm, 40.4% of those with diabetes, and 20.7% of those with 10-year Framingham Risk Scores of over 20%. Statin underuse and poor cholesterol control contributes to an estimated 635,000 new coronary events, nearly 800,000 new or recurrent strokes, and approximately one in every six deaths each year.[@b7-vhrm-10-615] Even after recent improvements in outcomes, heart disease remains the number one killer of Americans for both men and women.[@b11-vhrm-10-615]

Resource utilization
--------------------

Significant health care resources are expended and costs are attributed to managing hypercholesterolemia and its related conditions each year. In 2009, over 12 million physician office visits were primarily focused on CHD, specifically coronary atherosclerosis, and nearly 100 million visits -- about one in every ten -- included a cholesterol test, exceeding both the number of visits requesting glucose or hemoglobin A1C testing.[@b12-vhrm-10-615] In 2010, over 1.3 million inpatient stays were primarily due to CHD, with over 3 million estimated procedures (percutaneous coronary intervention, bypass, catheterizations, and placement of defibrillators and pacemakers) being completed throughout the year.[@b8-vhrm-10-615] In order to address disease related to high cholesterol levels, nearly 25% of adults in America now take some form of cholesterol-lowering medication;[@b13-vhrm-10-615] however, a significant number of adults with hypercholesterolemia still go untreated.[@b9-vhrm-10-615] Current projections suggest that direct medical and indirect costs due to CHD will approach US \$130 billion by the end of 2015, and this figure is expected to exceed US \$150 billion by the end of this decade.[@b14-vhrm-10-615] Significant efforts must be made to address the substantial impact that hypercholesterolemia has on Americans and the US health care system.

Current treatment
-----------------

Treatment recommendations for hypercholesterolemia have recently undergone a sea change. The new American College of Cardiology/American Heart Association (ACC/AHA) guidelines are somewhat controversial, and many providers are reasonably confused about which guidelines to follow and who to treat.[@b15-vhrm-10-615]--[@b17-vhrm-10-615] As shown in [Table 1](#t1-vhrm-10-615){ref-type="table"}, the most widely accepted Advanced Treatment Panel III (ATP-III) cholesterol treatment guidelines of the National Cholesterol Education Program recommend that approximately one-third of US adults (43.2 million) undertake medication therapy for high cholesterol, whereas the most recent ACC/AHA guidelines recommend that over half of American adults (56.0 million) undertake treatment.[@b18-vhrm-10-615] Extrapolation from the National Health and Nutrition Examination Survey population suggests that the new guidelines for hypercholesterolemia would recommend medication therapy to 87.5% of men aged 60--75 years and 53.6% of women in this age range.[@b18-vhrm-10-615] Similar extrapolation from the Rotterdam Study cohort of adults aged 55 years and older suggests that 96.4% of men and 65.8% of women would require treatment under the ACC/AHA guidelines compared with 66.1% of men and 35.5% of women for the ATP-III and 66.1% of men and 39.1% of women for the European Society of Cardiology (ESC) guidelines.[@b17-vhrm-10-615],[@b19-vhrm-10-615],[@b20-vhrm-10-615] Although experts generally support the largely concordant aggressive ACC/AHA, ATP-III, and ESC treatment recommendations for secondary prevention in patients with CHD or arteriosclerotic cardiovascular disease (ASCVD), and for primary prevention in the highest-risk groups, many express doubts regarding the appropriateness of recommendations for lower-risk groups.[@b15-vhrm-10-615]--[@b17-vhrm-10-615],[@b21-vhrm-10-615]

Debates regarding the ACC/AHA guidelines largely center on their methods for risk estimation. Critics note that the ASCVD pooled cohort risk equations, while generally showing fair discrimination, systematically overestimate risk, thereby overstating the need for treatment.[@b15-vhrm-10-615]--[@b17-vhrm-10-615],[@b21-vhrm-10-615],[@b22-vhrm-10-615] For the highest-risk group with clinical CHD/ASCVD, as few as five to ten patients would need to be treated for 10 years to prevent one heart attack in that period (number needed to treat \[NNT\] range: five to ten), but for relatively low-risk patients for whom medication therapy is recommended under the guidelines, NNT approaches 300--500 to prevent one heart attack in 10 years of therapy.[@b23-vhrm-10-615]--[@b25-vhrm-10-615] High NNTs for cholesterol medication therapy in low to moderate risk groups raise appropriate concerns regarding the application of these thresholds for treatment indiscriminately in individual patients. However, even using the more conservative ATP-III and ESC recommendations for treatment ([Table 1](#t1-vhrm-10-615){ref-type="table"}), the need for treatment is immense; by all accounts, high cholesterol represents a major public health problem.

However, the need for long-term treatment with statin medications in order to confer benefit makes concerns regarding cholesterol medication adherence particularly acute. Medication treatment for the primary and secondary prevention of CHD is daily, and it typically must be continued for 10--30 years on a daily basis to confer benefit. In addition, unlike therapy for acute symptomatic conditions, no symptomatic improvements are associated with therapy for high cholesterol. To the contrary, some patients experience adverse effects, including myalgias, rhabdomyolysis, nausea and vomiting, liver toxicity, increased incidence of diabetes, and mental status changes. Furthermore, therapy can be associated with potentially serious drug--drug interactions; however, recent summaries of the evidence suggest that statins are not associated with significant levels of serious adverse effects, and they are widely considered safe.[@b21-vhrm-10-615],[@b26-vhrm-10-615]

Taken together, these considerations -- high prevalence of the condition, treatment burden (requirement of daily medication), large time lag with little or no benefit for most individuals, lack of symptomatic benefit, and adverse medication effects -- make medication adherence for hypercholesterolemia a major public health problem. A population-based care approach demands that we find ways to deliver this proven effective preventive care approach to large populations with efficiency.

Adherence
=========

While multiple pharmaceutical treatment options are available to patients with hypercholesterolemia, the effectiveness of these treatments is limited by the extent to which patients adhere to the medication regimen prescribed by their provider. For patients with chronic conditions, including high cholesterol, this refers to both the daily taking of medication, as well as to the initiation and ongoing prescription filling of long-term therapies. Multiple studies have described the extent of nonadherence in patients with hypercholesterolemia and have provided estimates in a variety of patient populations, as well as insight into contributing factors.

Across studies, estimates for adherence or persistence to cholesterol-lowering medications have been observed to range depending on the underlying conditions, point of therapy, and the method used to assess medication use. When averaged across studies examining lipid-lowering therapies, adherence (as defined by the achievement of a medication possession ratio greater than 80%) was achieved in approximately 50% of patients examined, with approximately two-thirds of patients remaining persistent at 1 year.[@b27-vhrm-10-615] After 9 months of newly initiated statin therapy, only 56% of patients remained persistent and declined even further after the first year; average adherence was also suboptimal and was below 60% across all patients.[@b28-vhrm-10-615] Similarly, among commercially insured adults, 43% never returned to statin therapy following an observed stoppage of at least 90 days.[@b29-vhrm-10-615]

An interesting pattern of medication use has also been observed in patients following a distinct cardiac event or with well-established disease. Even though the odds of adherence have been shown to be slightly higher after a hospitalization, issues with remaining adherent appear relatively soon after discharge.[@b30-vhrm-10-615]--[@b32-vhrm-10-615] In a study of patients discharged for acute myocardial infarction, primary nonadherence (the failure to initiate a prescribed therapy) was suboptimal and over 10% of patients failed to fill their lipid-lowering agent 1 week after discharge; fill rates did not reach 90% until 30 days postdischarge.[@b33-vhrm-10-615] In another multicenter, prospective cohort study, similarly poor fill rates were observed prior to this, where approximately 70% of postmyocardial infarction patients had filled their statin 1 month after discharge.[@b34-vhrm-10-615] Among patients with established coronary artery disease, adherence has been observed to decline sharply in the first 6 months following initial therapy.[@b30-vhrm-10-615] At 18 months of planned statin therapy, nearly 30% of men with CHD within the Veteran Affairs system remained adherent; the odds of poor adherence were particularly high among new users of statins.[@b35-vhrm-10-615] Such ranges in estimates add weight to the prominence of the nonadherence problem in patients with hypercholesterolemia.

The result of significant departures from adherence to prescribed treatment regimens is an increase in odds of the patients experiencing detrimental health outcomes. A meta-analysis of adherence studies of patients with hypercholesterolemia found that adherence to therapy was related to a 25% decrease in the risk for a null or poor outcome compared to those who were nonadherent.[@b36-vhrm-10-615] Similarly, following hospitalization for acute myocardial infarction, statin nonadherence has been associated with an up to 25% increased hazard for mortality;[@b37-vhrm-10-615] a significant increase in the risk of hospitalization and mortality has also been observed in patients with coronary artery disease due to nonadherence to statins.[@b38-vhrm-10-615] Conversely, a protective effect of adherence against recurrent myocardial infarction, cardiovascular hospitalization, or death has been observed in multiple studies, with the odds of some outcomes increasing as adherence worsens.[@b39-vhrm-10-615],[@b40-vhrm-10-615]

Furthermore, decreased levels of adherence to hypercholesterolemia medications have been associated with a general increases in medical costs; estimates of avoidable costs for this condition due to medication nonadherence exceed those for hypertension and diabetes combined.[@b5-vhrm-10-615] However, patients remaining adherent to statin therapy have been associated with lower all-cause health care costs, particularly when compared to those following their therapy less than 60% of the time.[@b40-vhrm-10-615] Considering both the physiological and economic outcomes of poor adherence to therapy, it is imperative that we better understand and address medication use behaviors in patients with hypercholesterolemia.

Multiple factors have been associated with and observed to impact regular medication taking in patients being treated with agents indicated for hypercholesterolemia ([Table 2](#t2-vhrm-10-615){ref-type="table"}). Across multiple studies, female patients and those who were currently smoking reported lower levels of or odds for being adherent to prescribed lipid-lowering agents; however, characteristics, such as patient's age, have been related to inconsistent results.[@b31-vhrm-10-615],[@b35-vhrm-10-615],[@b41-vhrm-10-615]--[@b43-vhrm-10-615] Other factors shown to be predictive of poorer adherence include perceived side effects and recent initiation of treatment.[@b35-vhrm-10-615],[@b43-vhrm-10-615] Conversely, the taking of fewer medications, initiation of therapy with other cardiovascular medications, and lower copayments or levels of cost sharing have been consistently associated with better adherence or persistence.[@b29-vhrm-10-615]--[@b31-vhrm-10-615],[@b33-vhrm-10-615],[@b41-vhrm-10-615],[@b44-vhrm-10-615] Additionally, a limited number of investigations have found associations between better levels of or odds for adherence and provider time during visits, perceived efficacy of therapy, and more frequent provider office visits.[@b31-vhrm-10-615],[@b32-vhrm-10-615],[@b43-vhrm-10-615],[@b44-vhrm-10-615] However, in spite of these observations, much remains to be understood about the significant factors that influence ongoing medication use in order to best design approaches to improve medication-taking behavior.

Intervention strategies
=======================

A variety of approaches have been used in efforts to improve adherence to hypercholesterolemia medications. A number of these efforts have been tied not only to changes in adherence, but also to improvements in LDL cholesterol and clinical outcomes.[@b45-vhrm-10-615] Recent studies have focused on assessing strategies including: pharmacist counseling; patient reminders; education using mailed materials or direct calling; and systems-based strategies such as the lowering of copayments. However, mostly varied results have been observed across studies in terms of altering medication use, and no single approach has led to consistently positive results.

Pharmacist interventions
------------------------

Pharmacist participation in encouraging adherence has been central in multiple studies. Specific involvement in interventions has leveraged numerous techniques, including phone calls, counseling, medication review, home visits, and comprehensive pharmacy care. Content for these efforts has focused on education, the importance of adherence, and prevention; thus far, information exchange has been either direct or delivered by mailed material, video, or over the phone.[@b46-vhrm-10-615]--[@b51-vhrm-10-615] Outcomes related to pharmacist involvement have been mixed, with short-term and long-term changes in medication use varying between investigations, with particular methods showing promise and certain populations realizing improvements. Across studies, the combined use of pharmacist counseling or follow-up with a focus on adherence led to the most notable changes in medication use, even though consistent and significant improvements were not universal.[@b46-vhrm-10-615]--[@b51-vhrm-10-615] Of particular importance are the improvements realized in newly initiated patients, as well as the changes observed compared to control after 12 months of intervention.[@b46-vhrm-10-615]--[@b48-vhrm-10-615],[@b50-vhrm-10-615] Such results suggest that pharmacist participation can lead to improvements in hypercholesterolemia medication use, but the most effective means to do so, as well as whether it is sensible for intervention at the onset of therapy or once treatment has begun, require further inquiry.

Reminder systems
----------------

Reminders, provided by several mediums, have also been widely applied and with similarly varied results; such encouragement was provided by pharmacists, phone calls, through the mail, and via the use of calendar reminders. Telephone reminders, particularly when given in conjunction with educational material, appear to be especially beneficial to ongoing medication use;[@b46-vhrm-10-615],[@b48-vhrm-10-615],[@b52-vhrm-10-615],[@b53-vhrm-10-615] however, universal and significant improvements have not been observed.[@b54-vhrm-10-615],[@b55-vhrm-10-615] Other forms of reinforcement, such as mailed feedback based on theoretical constructs, have also led to positive improvements, but further inquiry into how behavioral theory applies to the taking of cholesterol medications is needed.[@b56-vhrm-10-615] Considering these results, and depending on the methods used, simple reminders provide a potentially cost-effective means by which medication adherence can be encouraged.

By and large, the evidence from published interventions targeting adherence to hypercholesterolemia medications suggests that patients may respond best to approaches involving pharmacists, as well as to interventions including more frequent contact throughout the treatment process. However, no comparative trials directly comparing the effectiveness of different provider types in promoting adherence have been done. Moreover, a combination of approaches -- rather than relying on one specific method -- may be best. Beyond these approaches, the simplifying of patient dosing regimens has also shown benefit;[@b57-vhrm-10-615] however, the number of doses required to be taken per day to remain adherent to hypercholesterolemia medications has become less of an issue in recent years due to the broad availability of once-daily treatments.

Systems-based strategies
------------------------

Systems-based strategies may have the most potential for effect. Promising systems-based strategies with high potential to improve cholesterol medication adherence include approaches to reduce cost sharing or to subsidize payments for essential medications, improve patient--provider communication, enhance patient-centered medical home (PCMH) infrastructure, and emphasize population-based preventive care instead of acute illness and hospital "rescue" care. However, for the most part, comparative effectiveness studies are lacking that directly compare promising alternative approaches.

Several studies have shown that even very small copayments may act as highly powerful disincentives to medication adherence for people with a low income. Tamblyn et al[@b58-vhrm-10-615] recently demonstrated that elimination of prescription copayments for low-income groups was among the strongest factors promoting adherence. Similarly, Eaddy et al[@b59-vhrm-10-615] summarized additional strong evidence that even very low copays of US \$3--US \$5 per prescription may strongly deter adherence in low-income populations. Most recently, Watanabe et al[@b60-vhrm-10-615] determined that statin adherence among the Veterans Affairs population was higher among those without out-of-pocket expenses; however, adherence dropped in cases where statins required a copayment, but other medications were free, suggesting the importance of the relative cost of medications for those on a multiple-drug regimen. Additionally, results from the MI FREEE Trial[@b61-vhrm-10-615] suggested that eliminating copayments for statins could also improve adherence following a defined cardiac event. This approach may not be feasible for the population at large, but it is certainly possible for patients at highest risk of nonadherence, and associated adverse events such as strokes and heart attacks are linked with nonadherence to cholesterol-lowering medications.[@b61-vhrm-10-615] The effects of copayment adjustments through the use of vouchers have also been investigated, and limited results suggest that the use of certain generic medications may be influenced by these means, but long-term impacts still require further inquiry.[@b62-vhrm-10-615] Studies are needed to directly test alternative strategies to subsidizing out-of-pocket costs for patients at highest risk and for assessing the impact of such subsidies on major clinical outcomes and overall health care costs.

In addition to copayment adjustment, financial incentives, such as pay-for-performance, have either been introduced or suggested as a means to encourage proper medication prescribing by physicians and subsequent filling and taking by patients. While prevalent among discussions in the literature, the impact of these mechanisms is fairly scant among published research that included medication measures; however, some results have indicated the positive impact that pay-for-performance can have when targeting physicians and incorporating medication-specific measures.[@b63-vhrm-10-615] Moving forward, due to the use of statin adherence in the calculation of Medicare Part D Star Ratings, increased insight into the impact of pay-for-performance is likely, as broader attention is paid to medication adherence.

Future methods
==============

While some progress has been realized with the methods employed to date, much room remains to improve the taking of hypercholesterolemia medications. While certain approaches appear to provide some benefit, the challenge that remains is one focused on creating the right combination of methods to target reasons for nonadherence at an individual level -- reasons that are likely to vary among patients. Therefore, the means to identify and tailor to individual needs will be equally imperative in creating focused interventions. Moreover, input and effort from multiple entities is needed to improve the odds of successful behavior change ([Figure 1](#f1-vhrm-10-615){ref-type="fig"}).

Practitioner role
-----------------

Avoidance of potential issues related to nonadherence in hypercholesterolemia begins with the efforts made by the prescribing physician immediately following diagnosis and the creation of an initial treatment plan. Primarily, a careful assessment of each patient's risk for cardiovascular disease will lead to more precise patient selection so that those with the most immediate need for medicinal therapy are selected for treatment. Such selection will allow the provider to naturally discuss the patient's immediate risk for detrimental outcomes and the role that cholesterol-lowering medications will play in the avoidance of these events. In these cases, it is imperative that physicians address both the medical benefits and direct costs associated with treatment so that patients have a complete set of data on which to base their treatment decision; concurrently, providers will need to be sensitive to the value placed on treatment by each patient and consider this factor when constructing an appropriate plan.

During encounters, physicians must also be cognizant of the potential for nonadherence based on the patient's response and success with previously suggested treatments, such as nonmedication options (for example, lifestyle modification) to address high cholesterol. Furthermore, the treatment discussion must also consider challenges experienced with medication taking in other conditions, if applicable. This will also open the door to an extended conversation about the potential barriers that individual patients may have, or anticipate having, with a proposed regimen, specifically the costs of treatment both immediately and over time. Considering the chronic nature of the condition that cholesterol-lowering medications treat, the cost of addressing disease and avoiding negative outcomes by remaining adherent may be substantial; the acknowledgment of and assistance in combating cost-related issues upfront may result in the increased likelihood of patient adherence. Beyond costs, patient-specific factors, such as perceptions about their condition, perceived efficacy of treatment, and other elements outlined above that have been linked with nonadherence, must also be acknowledged to avoid future disruptions in therapy. Recognition of these factors will aid the provider in establishing a plan that may better suit the patient's needs and allow for the opportunity to have a frank discussion about the importance of remaining adherent to the agreed-upon treatment plan.

Once therapy is initiated, the monitoring of patient progress may be beneficial to the treatment process. Physicians should consider the use of electronic health record systems and the provision of pharmacy claims to observe refill behavior in patients over time. In this manner, alerts may be provided and then used to communicate with patients whose adherence may be wavering -- either office staff or the provider may determine if medical attention is necessary, such as changes in therapy or if there is need for interventions to improve use -- in order to uncover potential issues that may have gone unaddressed or those that have developed between encounters. Such a real-time approach may not only lead to improved medication taking, but also limit the patient's risk for an event that would have otherwise been unknown.

Emerging opportunities
----------------------

Moving forward, opportunities to address medication nonadherence may build off of previous findings, such as those outlined above, but new approaches are likely to also employ emerging technologies and improved communication channels. In recent years, an increasing number of studies have examined the potential applications of mobile phones throughout the treatment process with positive results observed in several conditions.[@b64-vhrm-10-615]--[@b66-vhrm-10-615] Considering the nearly ubiquitous nature of these devices, as well as the varied functions provided by advanced platforms, multiple opportunities exist to introduce mobile communication into individual regimens. Options to leverage mobile devices include automated reminders, personalized education and information, clinical data exchange, and disease tracking. By engaging patients further in their condition and treatment in this manner, it may be possible to improve how closely they follow prescribed regimens.

Research, as reviewed herein, has shown that pharmacists may have a profound impact on the taking of medications in persons with hypercholesterolemia. Considering this, care teams may benefit from including ambulatory care pharmacists in the treatment process, offering an additional layer of medicinal guidance, the provision of medication therapy management (MTM) services, and the potential for increased contact throughout the patient's treatment.[@b67-vhrm-10-615] Other providers, such as nurse case managers, could also be tapped to assist in this process, having shown positive impacts in patients with dyslipidemia.[@b68-vhrm-10-615],[@b69-vhrm-10-615] Including both types of these practitioners in the patient care plans would provide more opportunities to interact with and encourage particular behaviors among patients, as well as promote the sharing of responsibility across providers, potentially leading to more efficient processes of care.

Furthermore, evidence suggests that other institutional and health policy factors may exert strong influences on adherence. Health care system overemphasis of acute illness or "sickness" care and hospital or "rescue" care results from disproportionately high reimbursements for procedures and tertiary care, while population-based primary and preventive care is underemphasized.[@b70-vhrm-10-615],[@b71-vhrm-10-615] As a result, in many communities, it is easier to get access to expensive emergency care and dialysis services than comprehensive primary care services that are most likely to emphasize cholesterol medication adherence.[@b72-vhrm-10-615] However, thus far, little data are available directly contrasting the impact of alternative payment mechanisms or alternative approaches to organizing health care services on adherence to essential preventive medications. Similarly, a lack of health system integration encouraged by the current payment approaches has resulted in poor communication between the inpatient and outpatient sectors, and poorly coordinated care for patients with the greatest need for adherence. Further studies are needed to directly test promising new models supporting improved care coordination and population-based care such as PCMH and accountable care organizations.

Early evidence suggests that increased emphasis on population-based primary care through investment in improved PCMH infrastructure may hold the key to improving adherence for chronic diseases like hypercho-lesterolemia.[@b73-vhrm-10-615] For example, Domino et al[@b74-vhrm-10-615] showed that PCMH care for asthma improved adherence for maintenance medication. Furthermore, a fundamental capacity for PCMH is the use of registries for disease tracking and outreach.[@b73-vhrm-10-615] Registries that are used to track and outreach patients with hypercholesterolemia have substantial capacity to improve processes and outcomes of care, yet they are, by and large, untested for hypercholesterolemia.

In addition, PCMH-based registries are hampered by a lack of electronic pharmacy refill data that could be easily harnessed in the PCMH setting to identify and outreach nonadherent patients. Bailey et al[@b75-vhrm-10-615] demonstrated that in the case of hypertension, electronic pharmacy refill information could be used to identify patients nonadherent to antihypertensives that are thereby at increased risk for stroke and death. Bailey et al, and others, have called for policy changes to give providers broader access to real-time pharmacy refill information that may be used to effectively identify potential predictors of nonadherence and, ultimately, improve care.[@b75-vhrm-10-615],[@b76-vhrm-10-615] Specific research is needed to determine whether providing broad access to electronic pharmacy refill information to all the key providers on the care team in real time can improve processes and outcomes of care for hypercholesterolemia.

Public reporting of standard quality metrics assessing treatment and control rates for hypercholesterolemia also has the potential to improve hypercholesterolemia care. Simple reporting of quality information has been shown to lead to solid improvements in care for multiple chronic conditions. There is every reason to expect that hypercholesterolemia care would undergo similar improvements just through improved transparency at the primary care level. Further studies are needed to test these and other PCMH approaches to improving adherence to recommended care for hypercholesterolemia and other chronic conditions.

Conclusion
==========

Nonadherence to hypercholesterolemia medications remains a prevalent public health issue. Particular approaches have been successful in improving medication-taking behaviors, but opportunities to improve adherence remain considering the varied reasons for suboptimal use. A combination of approaches that leverages effective physician communication with pharmacist involvement, ongoing patient interaction and, potentially value-based cost sharing, may lead to improved medication use and better health outcomes. Systems-based strategies to promoting adherence with cholesterol-lowering medications may possibly be the most promising over the long term, but reliable assessments of these approaches are lacking. Further studies are urgently needed to directly test promising systems-based strategies to improve adherence to potentially life-saving cholesterol medication for those at highest risk of both nonadherence and cardiovascular events.
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###### 

Recommended treatment strategies for hypercholesterolemia

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                        2001 Advanced Treatment Panel III/National Cholesterol Education Program guidelines[@b77-vhrm-10-615],[@b78-vhrm-10-615]                  2013 American College of Cardiology/American Heart Association guidelines[@b79-vhrm-10-615],[@b80-vhrm-10-615]
  ------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Populations treated                   1\. Adults with CHD or CHD risk equivalents and LDL-C \>100 mg/dL\                                                                        1\. Adults with clinical atherosclerotic cardiovascular disease\
                                        2. Adults with 2+ CHD risk factors (10-year risk 10%--20%) and LDL-C \>130 mg/dL\                                                         2. Adults with primary elevations of LDL-C \>190 mg/dL\
                                        3. Adults with 2+ CHD risk factors (10-year risk \<10%) and LDL-C \>160 mg/dL\                                                            3. Adults with diabetes, aged 40--75 years, with LDL-C 70--189 mg/dL and without clinical ASCVD\
                                        4. Adults with 0--1 CHD risk factors and LDL-C \>190 mg/dL                                                                                4. Adults without clinical ASCVD or diabetes with LDL-C 70--189 mg/dL and estimated 10-year ASCVD risk \>7.5%

  Risk assessment method                LDL-C and CHD risk factor assessment based on Framingham data                                                                             CVD risk factor assessment based on pooled CVD data including total cholesterol

  10-year risk calculator               Framingham[@b81-vhrm-10-615]                                                                                                              Pooled cohort equations[@b82-vhrm-10-615]

  Recommended treatments                Lifestyle modification with addition of cholesterol-lowering medications (primarily statins) based on LDL cholesterol and risk category   Statin cholesterol-lowering medications for all groups with statin therapy intensity determined based on risk category alone plus lifestyle modification

  Treatment monitoring                  Yes, treat to recommended LDL levels                                                                                                      Yes, treat independently of observed LDL levels

  Recommended adult                     Total: 43.2 million people (37.5%)                                                                                                        Total: 56.0 million (48.6%)

  United States treatment               Aged 40--59 years: 20.3 million people (27.0%)                                                                                            Aged 40--59 years: 22.3 million (29.7%)

  population (2010)[@b18-vhrm-10-615]   Aged 60--75 years: 13.5 million people (47.8%)                                                                                            Aged 60--75 years: 21.9 million (77.3%)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** CHD, coronary heart disease; LDL-C, low-density lipoprotein cholesterol; ASCVD, arteriosclerotic cardiovascular disease; CVD, cardiovascular disease; LDL, low-density lipoprotein.

###### 

Challenges to cholesterol medication adherence

  Category                                               Barrier
  ------------------------------------------------------ -----------------------------------
  System factors                                         Higher cost sharing or copayments
  Poor patient--provider communication                   
  Lack of patient-centered medical home infrastructure   
  Acute illness (sickness care) focus                    
  Hospital (rescue care) focus                           
  Condition and treatment factors                        Perceived efficacy
  Newly initiated patients                               
  Number of medications                                  
  Perceived side effects                                 
  Timing of medication initiation                        
  Patient-level factors                                  Sex
  Smoking status                                         
